Navigating Distrust: Pharma in the Age of Social Media

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.

LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.

The traditional biopharma approach focused primarily on physician detailing and securing favorable payer contracts, has become inadequate in today’s market.

Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.

Emrelis is the first FDA-approved treatment for previously treated patients with locally advanced or metastatic non-squamous non-small cell lung cancer with high c-Met protein overexpression.

The organization believes that the proposed cuts will be harmful to Americans suffering from mental illnesses.